Sarepta Therapeutics Inc. said a second patient has died of acute liver failure after being treated with its gene therapy for a rare muscle disorder.
The death comes three months after a teenage boy died after getting the one-time treatment, Elevidys. Both cases occurred in patients with Duchenne muscular dystrophy who are unable to walk, the company said.
www.bloomberg.com
#Sarepta #Reports #Death #Patient #Gene #Therapy
